505 related articles for article (PubMed ID: 28167755)
41. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
Echeverria I; Liu Y; Gabelli SB; Amzel LM
FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
[TBL] [Abstract][Full Text] [Related]
42. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
43. Mutations in PIK3R1 can lead to APDS2, SHORT syndrome or a combination of the two.
Bravo García-Morato M; García-Miñaúr S; Molina Garicano J; Santos Simarro F; Del Pino Molina L; López-Granados E; Ferreira Cerdán A; Rodríguez Pena R
Clin Immunol; 2017 Jun; 179():77-80. PubMed ID: 28302518
[TBL] [Abstract][Full Text] [Related]
44. Genetic Defects in Phosphoinositide 3-Kinase δ Influence CD8
Cannons JL; Preite S; Kapnick SM; Uzel G; Schwartzberg PL
Front Immunol; 2018; 9():1758. PubMed ID: 30116245
[TBL] [Abstract][Full Text] [Related]
45. Clinical and immunological assessment of APDS2 with features of the SHORT syndrome related to a novel mutation in
Szczawińska-Popłonyk A; Bernat-Sitarz K; Schwartzmann E; Piechota M; Badura-Stronka M
Allergol Immunopathol (Madr); 2022; 50(4):1-9. PubMed ID: 35789397
[TBL] [Abstract][Full Text] [Related]
46. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS).
Burke JE; Williams RL
Adv Biol Regul; 2013 Jan; 53(1):97-110. PubMed ID: 23194976
[TBL] [Abstract][Full Text] [Related]
47. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
48. Mutations in the adaptor-binding domain and associated linker region of p110δ cause Activated PI3K-δ Syndrome 1 (APDS1).
Heurtier L; Lamrini H; Chentout L; Deau MC; Bouafia A; Rosain J; Plaza JM; Parisot M; Dumont B; Turpin D; Merlin E; Moshous D; Aladjidi N; Neven B; Picard C; Cavazzana M; Fischer A; Durandy A; Stephan JL; Kracker S
Haematologica; 2017 Jul; 102(7):e278-e281. PubMed ID: 28428270
[No Abstract] [Full Text] [Related]
49. Early diagnosis of PI3Kδ syndrome in a 2 years old girl with recurrent otitis and enlarged spleen.
Saettini F; Pelagatti MA; Sala D; Moratto D; Giliani S; Badolato R; Biondi A
Immunol Lett; 2017 Oct; 190():279-281. PubMed ID: 28842185
[TBL] [Abstract][Full Text] [Related]
50. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
[TBL] [Abstract][Full Text] [Related]
51. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
52. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
[TBL] [Abstract][Full Text] [Related]
53. Novel PIK3CD mutations affecting N-terminal residues of p110δ cause activated PI3Kδ syndrome (APDS) in humans.
Takeda AJ; Zhang Y; Dornan GL; Siempelkamp BD; Jenkins ML; Matthews HF; McElwee JJ; Bi W; Seeborg FO; Su HC; Burke JE; Lucas CL
J Allergy Clin Immunol; 2017 Oct; 140(4):1152-1156.e10. PubMed ID: 28414062
[No Abstract] [Full Text] [Related]
54. Isoform-selective induction of human p110δ PI3K expression by TNFα: identification of a new and inducible PIK3CD promoter.
Whitehead MA; Bombardieri M; Pitzalis C; Vanhaesebroeck B
Biochem J; 2012 May; 443(3):857-67. PubMed ID: 22375552
[TBL] [Abstract][Full Text] [Related]
55. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
56. A human immunodeficiency caused by mutations in the PIK3R1 gene.
Deau MC; Heurtier L; Frange P; Suarez F; Bole-Feysot C; Nitschke P; Cavazzana M; Picard C; Durandy A; Fischer A; Kracker S
J Clin Invest; 2014 Sep; 124(9):3923-8. PubMed ID: 25133428
[TBL] [Abstract][Full Text] [Related]
57. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma.
Durandy A; Kracker S
Blood; 2020 Feb; 135(9):638-643. PubMed ID: 31942637
[TBL] [Abstract][Full Text] [Related]
58. Probing the dynamic regulation of peripheral membrane proteins using hydrogen deuterium exchange-MS (HDX-MS).
Vadas O; Burke JE
Biochem Soc Trans; 2015 Oct; 43(5):773-86. PubMed ID: 26517882
[TBL] [Abstract][Full Text] [Related]
59. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
Huang CH; Mandelker D; Gabelli SB; Amzel LM
Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
[TBL] [Abstract][Full Text] [Related]
60. Idelalisib inhibits vitreous-induced Akt activation and proliferation of retinal pigment epithelial cells from epiretinal membranes.
Xin T; Han H; Wu W; Huang X; Cui J; Matsubara JA; Song J; Wang F; Colyer M; Lei H
Exp Eye Res; 2020 Jan; 190():107884. PubMed ID: 31786159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
